The COVID-19 pandemic has galvanized intense effort to prevent and treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.[1] The ubiquity of SARS-CoV-2 in the human population only makes the development of efficacious and broadly accessible medical countermeasures more imperative.[2] The SARS-CoV-2 spike protein is a critical target for therapeutic intervention, which mediates the virus entry by binding to the host angiotensin-converting enzyme 2 (ACE2). This evidence concerns the gene ACE2 and COVID-19.